Setrobuvir
- Generic Name
- Setrobuvir
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C25H25FN4O6S2
- CAS Number
- 1071517-39-9
- Unique Ingredient Identifier
- T5B2GI8F84
- Background
Setrobuvir has been used in trials studying the treatment of Hepatitis C, Chronic.
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Setrobuvir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Genotype 1 Chronic Hepatitis C
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-07-19
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 283
- Registration Number
- NCT01903954
A Safety And Pharmacokinetic Study of Setrobuvir Alone and In Combination With Ritonavir-Boosted Danoprevir in Subjects With Mild Hepatic Impairment Compared to Healthy Controls
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-10-25
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 18
- Registration Number
- NCT01714154
A Relative Bioavailability Study of Setrobuvir Tablet Formulation Versus Reference Setrobuvir Capsule Formulation in Healthy Volunteers
- First Posted Date
- 2012-06-05
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT01612143
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath